Established in 1988, BSE-listed Remedium Lifecare is evolving from raw material trading to a CDMO, enhancing R&D and quality control. Nearly 50% subscribed rights issue supports this strategic shift towards global expansion, particularly in the UK and Europe, evidenced by a recent ₹182.7 crore export contract. Remedium's Singapore subsidiary is also adopting green chemistry for API manufacturing.